• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Self-associated functional acrylic acrylic copolymers and terpolymers and their use as vehicles for bioactive compounds. The present invention relates to a family of copolymers and antiphilic terpolymers that form nanoactive multi-micel nanoparticles of nanometric size, constituted by synthetic polymer systems derived from functional acrylic monomers containing α -tocopherol (vitamin E) as bioactive and hydrophobic component, and hydrophilic monomers of very variable composition, preferably consisting of N-vinyl pyrrolidone, N-vinyl caprolactam, N-vinyl imidazole as well as mixtures of methacrylate copolymers of vitamin E and N-vinyl pyrrolidone with the corresponding terpolymers. These compounds can be used as controlled release systems for the administration of bioactive compounds. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2735638A1
    申请号:ES201830594
    申请日:2018-06-18
    公开日:2019-12-19
    发明作者:Roman Del Barrio Julio San；De Armas Maria Rosa Aguilar；Suay Raquel Palao；Alberto Nakal
    申请人:Alodia Farm S L；Centro De Investig Biomedica En Red En Bioingenieria Biomateriales Y Nanomedicina Ciber Bbn；Consejo Superior de Investigaciones Cientificas CSIC；Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina CIBERBBN；
    IPC主号:
    专利说明:

    [0001]
    [0002]
    [0003]
    [0004] The present invention relates to a family of amphiphilic copolymers and terpolymers that form bioactive multi-micellar nanoparticles of nanometric size, consisting of synthetic polymer systems derived from functional acrylic monomers containing a-tocopherol (vitamin E) as a bioactive and hydrophobic component, and hydrophilic monomers of very variable composition, preferably constituted by N-vinyl pyrrolidone, N-vinyl caprolactam, N-vinyl imidazole as well as mixtures of methacrylate copolymers of vitamin E and N-vinyl pyrrolidone with the corresponding terpolymers. These compounds can be used as controlled release systems for the administration of bioactive compounds.
    [0005]
    [0006] BACKGROUND OF THE INVENTION
    [0007]
    [0008] The advances that nanotechnology has experienced in recent years have allowed the development of very specific systems for very targeted applications in the area of regenerative medicine, offering new biomedical treatment strategies that provide very innovative and interesting solutions to problems of difficult prognosis and effective treatment. , as are the intra-articular applications to improve the biomechanics of joints, as well as to ensure an effective osteo-articular regeneration treatment, or treatments at the epidermal level to improve the conditions of the epidermis.
    [0009]
    [0010] A-tocopherol (vitamin E) is highly hydrophobic, has very low or no solubility in physiological media and, therefore, is difficult to administer and maintain in the physiological environment actively. Acrylic derivatives of vitamin E (either acrylate or methacrylate) have the same hydrophobic character, but due to their reactivity on the part of the acrylic component, it can be used to prepare polymer systems in a wide range of compositions by polymerization with the relevant vinyl derivatives between those considered N-vinyl pyrrolidone and N-vinyl caprolactam. The result is a polymeric system of high molecular weight, biocompatible and of character Very notable amphiphilic, depending on the content in the hydrophilic and hypophobic components. As a result, the system behaves as a macromolecular compound, of controlled molecular weight and purely amphiphilic character, which under physiological conditions self-associates to form nanoparticles of controlled size depending on the methodology applied in its preparation. The bioactive component (vitamin E) is therefore chemically anchored to a micellar system that can offer on the one hand the ability to self-assemble, and at the same time offers a very considerable antioxidant activity at the cellular level. Depending on the composition and molecular weight it is possible to prepare stable self-assembled nanoparticles in physiological conditions with varying sizes that can range between 50 nm and 500 nm. These nanoparticles, stable in aqueous media and physiological medium, can be efficiently dispersed in gel-shaped polymer solutions or high viscosity solutions with reabsorbable and biodegradable polymers such as chitosan, hyaluronic acid, chondroitin sulfate, gelatin, gum arabic, Aloe Vera , and cellulosic derivatives such as methyl cellulose, carboxymethyl cellulose, starches, dextrins, etc.
    [0011]
    [0012] The following scientific article “Anticancer and Antiangiogenic Activity of Surfactant-Free Nanoparticles Based on Self-Assembled Polymeric Derivatives of Vitamin E: Structure-Activity Relationship '' R. Palao-Suay et al. Biomacromolecules (2015) 16 1566-1581 describes acrylic polymeric derivatives bearing a-tocopherol of up to 20% of the total monomers in the feed, where the a-tocopherol is directly linked to the acrylic group of the polymeric derivative. The application of these systems is oriented in relation to the antioxidant capacity associated with the incorporated a-tocopherol.
    [0013]
    [0014] Therefore, it is of great interest from an applied point of view to develop systems that offer the ability to self-assemble, and simultaneously be carriers of the antioxidant component par excellence (vitamin E), and can be used in the form of nanoparticles as vehicles for vectorization and controlled and directed release of other bioactive components that can be loaded or added to the nanoparticles in appropriate proportions, significantly reducing their toxicity and allowing their application at a specific point in the body (targeted and localized application), thereby substantially reducing their toxic effects secondary and greater efficiency is achieved than would be obtained by applying bioactive components applied freely or in isolation.
    [0015] DESCRIPTION OF THE INVENTION
    [0016]
    [0017] The present invention describes the use of a family of amphiphilic copolymers and terpolymers that under physiological conditions are capable of forming polymer micelles of micrometer or nanometer size and that are constituted by acrylic monomers derived from the a-tocopherol molecule and monomers highly hydrophilic such as N-vinyl pyrrolidone and / or N-vinyl caprolactam, vinyl imidazole and other hydrophilic vinyl compounds. This family of copolymers and terpolymers has a dual activity (antioxidant and amphiphilic) that offers the possibility of being used as vehicles for other active ingredients with analgesic, anti-inflammatory, activators of tissue regeneration processes, antibiotics, anti-proliferative, antimicrobial, etc.
    [0018]
    [0019] In a first aspect, the present invention relates to a polymeric compound of formula (I):
    [0020]
    [0021]
    [0022]
    [0023] where R 1 is selected from hydrogen and linear or branched C 1 -C 4 alkyl;
    [0024] R 2 is vitamin E or -X-vitamin E, where X is the group - [(CH 2 ) aR 3 - (CH 2 ) bR 4 ] c -, where a and b have a value independently selected from 2 to 6, c it has a value selected from 1 to 6;
    [0025] R 3 and R 4 are independently selected from C = O, OC = O;
    [0026] G and J are the same or different hydrophilic monomers;
    [0027] m, n and n 'represent the molar fraction of each of the units delimited by the symbols [] in the final composition of the polymeric compound, being (m + n + n') = 1 and * is understood as the consecutive repetition of said units.
    [0028] In the present invention the term "vitamin E" refers to a family comprising a-tocopherol, p-tocopherol, and-tocopherol, 5-tocopherol, a-tocotrienol, p-tocotrienol, ptocotrienol and 5-tocotrienol. , a-tocopherol is the form that remains active in the body, making it the preferred form of vitamin E. It acts as a fat-soluble antioxidant that prevents lipid peroxidation of polyunsaturated fatty acids in cell membranes. next:
    [0029]
    [0030]
    [0031]
    [0032]
    [0033] In the present invention the a-tocopherol molecule (vitamin E) is attached to an acrylic moiety through enzymatically hydrolysable bonds, R 2 , which prevents its accumulation in the organism, since it gives rise to products totally soluble in the physiological environment. The advantage of these acrylic monomers carrying a-tocopherol is, therefore, their solubility in physiological medium, which allows them to be eliminated from the body using the more normal metabolic pathway, being commonly eliminated by filtration through the kidney if they have a adequate molecular weight.
    [0034]
    [0035] In a preferred embodiment, vitamin E is alpha-tocopherol.
    [0036]
    [0037] In another preferred embodiment, G and J are independently selected from the following group: N-vinyl pyrrolidone, N-vinylcaprolactam, 1-vinylimidazole and N, N-dimethylacrylamide, N-isopropylacrylamide, 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate, polyethylene acrylate, polyethylene acrylate of polyethylene glycol, 2-hydroxypropyl methacrylate, N-ethylmorpholine methacrylate, N-ethylmorpholine acrylate, N-hydroxyethyl pyrrolidone, N-hydroxyethyl pyrrolidone acrylate.
    [0038]
    [0039] In another preferred embodiment, the compound of the invention is the compound of formula (II):
    [0040]
    [0041]
    [0042] where Ri, m, n and n ’are as defined above.
    [0043] In another preferred embodiment, the compound of the invention is the compound of formula (III):
    [0044]
    [0045]
    [0046]
    [0047] or its isomers or salts,
    [0048] where R 1 , m, n and n 'are as defined above.
    [0049] In another preferred embodiment, m has a value of 0.15.
    [0050] In another preferred embodiment, n has a value between 0.00 and 0.85.
    [0051]
    [0052] In another preferred embodiment, n ’has a value between 0.00 and 0.85.
    [0053]
    [0054] Another aspect of the invention relates to a multi-micellar nanoparticle comprising the polymeric compound as defined above.
    [0055]
    [0056] In a preferred embodiment, the polymeric compound of the multi-micellar nanoparticle is the polymeric compound of formula (II).
    [0057]
    [0058] In another preferred embodiment, the polymeric compound of the multi-micellar nanoparticle is the polymeric compound of formula (III).
    [0059]
    [0060] In another preferred embodiment, the multi-micellar nanoparticle further comprises a bioactive compound.
    [0061]
    [0062] In a more preferred embodiment, the bioactive compound is selected from the following group: methylprednisolone, dexamethasone, cortisone, ibuprofen, naproxen, flurbiprofen, ketoprofen, vitamin C, polyphenols, carnosic acid, astaxanthin, vitamin B1, vitamin B6, vitamin B12, derivatives of p-carotene, lutein, allantoin, vitamin A, folic acid, vancomycin, rifampin, linezolid, quaternary ammonium salts, chlorhexidine.
    [0063]
    [0064] Another aspect of the invention relates to a controlled release system of bioactive compounds comprising the multi-micellar nanoparticle as described above.
    [0065]
    [0066] Another aspect of the invention relates to a pharmaceutical composition comprising the controlled release system as described above.
    [0067]
    [0068] The systems set forth in this patent are constituted by copolymers formed by a monomeric component derived from acrylic α-tocopherol (vitamin E) and a vinyl monomer, which may be among others N-vinyl pyrrolidone, N-vinyl caprolactam or a mixture of vinyl compounds that will be an integral part of copolymeric or terpolymer systems of controlled composition and amphiphilic character, with a balance of hydrophilic and hydrophobic sequence components that will depend directly on the composition of the systems with the three components, acrylic derivative of vitamin E, N-vinyl pyrrolidone and N-vinyl caprolactam , and the incorporation of other vinyl monomers described in the patent body may also be considered.
    [0069]
    [0070] The nanoparticulate systems considered in this patent have the property of self-associating under physiological conditions to give rise to stable multimicellar nanoparticles, and also the ability to disassociate in a reasonable period of time, offering an adequate way of eliminating the systems once that have exerted their main function in the biomedical applications that are determined.
    [0071]
    [0072] By "copolymer" is understood in the present invention a macromolecule composed of two different repetitive units, called monomers, which can be joined in different ways by means of chemical bonds. The monomers that form the copolymer can be distributed randomly or periodically. Similarly, a "terpolymer" results from the simultaneous polymerization reaction of three monomers of a different chemical nature where the ionic, hydrophilic or lipophilic character of the system as a whole can be modified according to the composition.
    [0073]
    [0074] The term "amphiphilic copolymer or terpolymer" refers to systems of two or three different monomers formed by lipophilic sequences or segments attached to hydrophilic segments of variable length.
    [0075]
    [0076] The polymeric compounds of the present invention have the quality of forming particles of nanometric or micrometric size, with a characteristic morphology consisting of a hydrophobic core and a hydrophilic cortex. They have an advantage to highlight, such as the size and morphology of micelles that can be modulated by controlling the molar composition and concentration of these polymer systems. Micelles of sizes between 50 and 500 nm are easily administrable by injection, in the area where they are required, or applied in aqueous dispersions or in hydrophilic gels topically or locally.
    [0077]
    [0078] The compounds of the present invention can be prepared in a wide range of Molar compositions, all of them have a good cytocompatibility and an appropriate micellar stability which allows them to be used not only as compounds with an antioxidant activity per se but also as vehicles for administration, and controlled and directed release of bioactive components and drugs.
    [0079]
    [0080] The compounds of formula (II) or (III) as described above can be obtained by a process comprising the following steps:
    [0081] a) Mixing of alpha-tocopherol with acrylic or methacrylic acid chloride in the presence of a catalyst and a reaction activator.
    [0082] b) Mixture of the acrylic monomer obtained in step a) with a hydrophilic monomer, in the presence of a reaction initiator.
    [0083]
    [0084] Preferably, the catalyst of step a) is a tertiary amine.
    [0085]
    [0086] Preferably, the reaction time of step a) has a duration between 1 and 60 hours.
    [0087]
    [0088] Preferably, step a) is performed at a temperature of 15 ° C to 60 ° C.
    [0089]
    [0090] Preferably, the initiator of step b) is a radical initiator (organic peroxide, azo compound, perester).
    [0091]
    [0092] Preferably, the catalyst concentration employed in (a) is between 0.01 and 1.5 equivalents. More preferably, the concentration of reaction activator employed in (a) is between 1.0 and 1.8 equivalents.
    [0093]
    [0094] Preferably, the concentration of monomer used in step (b) is between 0.1 and 10 M. More preferably, the concentration of initiator used in step (b) is between 0.01 and 0.1 M.
    [0095]
    [0096] The multi-micellar nanoparticles described above can be obtained by a process in which the polymeric compound of formula (I) is dissolved in an organic solvent and nanoprecipitated in an aqueous medium or physiological medium miscible with the organic solvent.
    [0097] Preferably, the organic solvent is miscible with water and is selected from the following group: dioxane, tetrahydrofuran dimethylsulfoside, and dimethylformamide.
    [0098]
    [0099] Preferably, the organic solvent is in a concentration of between 1 and 40 mg / ml. in the mix.
    [0100]
    [0101] Preferably, the aqueous medium is in a concentration of between 0.2 and 10 mg / ml. in the mix
    [0102]
    [0103] Preferably, a mixture of poly (MVE-co-VP) copolymer (15:85) (feed molar) and terpolymers represented by formulas (II) and (III) is used.
    [0104]
    [0105] Throughout the description and the claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figures are provided by way of illustration, and are not intended to be limiting of the present invention.
    [0106]
    [0107] BRIEF DESCRIPTION OF THE FIGURES
    [0108]
    [0109] FIG. 1. Shows the scheme of the synthesis of methacrylic monomer derived from the a-tocopherol molecule, MVE. Similar schemes can be proposed for the corresponding acrylic derivatives AVE, ATOS, MTOS.
    [0110]
    [0111] FIG. 2. Shows the 1 H-NMR spectrum (400 MHz, CDCl 3) of the methacrylic monomer derived from the a-tocopherol molecule (MVE).
    [0112]
    [0113] FIG. 3. Shows the 1 H-NMR spectrum (400 MHz, CDCl 3) of the poly (MVE-co-VP) copolymer (15:85 molar in feed, Cop-85).
    [0114]
    [0115] FIG. 4. It shows the 1H-NMR spectrum (400 MHz, CDCl3) of the poly (MVEco-VP- co-VC) polypolymer terpolymer in feed (15: 83: 2).
    [0116]
    [0117] FIG. 5. Displays scanning electron microscopy (SEM) images (a) and atomic force microscopy (AFM) (b) of nanoparticles obtained with copolymers and methacrylic terpolymers derived from the a-tocopherol and W-vinylpyrrolidone (VP) and N-vinyl caprolactam poly (MVE-co-VP-co-VC) molecule .
    [0118]
    [0119] FIG. 6. Shows the results of the viability test of human fibrobroblasts exposed to nanoparticles obtained from poly (MVE-co-VP) copolymers and poly (MVE-co-VP-co-VC) terpolymers. AlamarBlue assay, the mean of the relative cell viability ± standard deviation (n = 8; *: p <0.05) is represented.
    [0120]
    [0121] FIG. 7. Comparison sample of particle size distributions obtained from the poly control copolymer (MVE-co-VP) over 4 weeks of storage in the refrigerator at 4 ° C.
    [0122]
    [0123] FIG. 8. Comparison sample of particle size distributions obtained from the poly control copolymer (MVE-co-VP) over 4 weeks of storage in the freezer at -20 ° C.
    [0124]
    [0125] FIG. 9. Sample of the comparison of the particle size distributions obtained from the poly control copolymer (MVE-co-VP) after lyophilization and keeping them under magnetic stirring for 2 h.
    [0126]
    [0127] FIG. 10. Comparison sample of the particle size distributions obtained from the poly control copolymer (MVE-co-VP) incorporating TPGS as a surfactant.
    [0128]
    [0129] EXAMPLES
    [0130]
    [0131] Next, the invention will be illustrated by tests carried out by the inventors, which demonstrates the effectiveness of the product of the invention.
    [0132]
    [0133] Example 1
    [0134]
    [0135] Synthesis of a methacrylic monomer derived from the a-tocopherol molecule (MVE) The monomer was prepared by reacting the a-tocopherol molecule with methacryloyl chloride in the presence of triethylamine. Dichloromethane was used as solvent. The The reaction scheme is shown in Figure 1.
    [0136]
    [0137] The a-tocopherol molecule (1 equivalent) and triethylamine (1.5 equivalents) in 150 ml of dichloromethane were introduced into a round bottom flask. Methacryloyl chloride (1.2 equivalents) was added slowly, dropwise, with constant stirring under a nitrogen atmosphere and using an ice bath. The reaction mixture was maintained for 24 hours at room temperature. After 24 hours, the reaction mixture was washed by successive extractions with NaOH and 1N HCl solutions and then the solvent was removed under reduced pressure. The resulting medium was redissolved in hexane and washed 3 times with the same HCl solution used previously in order to improve the purification efficiency. The overall reaction yield was greater than 90%.
    [0138]
    [0139] Figure 2 shows the spectrum of the MVE with the assignment of the resonance signals that verify the correct synthesis of the monomer. The signals corresponding to the vinyl protons and the protons of the group (CH 3 ) of the acrylic group can be clearly observed in the spectrum.
    [0140]
    [0141] Synthesis of the carrier copolymer of the alpha-tocopherol poly (MVE-co-VP) molecule Copolymers were prepared by reaction of the obtained MVE monomer and N- vinyl pyrrolidone (VP) as hydrophilic monomer from a composition in the MVE feed: VP (% -molar) of 15:85.
    [0142]
    [0143] The copolymer was prepared by radical polymerization at high conversion. The reaction was carried out by dissolving the monomers in dioxane (1 M) using 2,2′-Azobisisobutyronitrile (AIBN) as initiator (1.5x10-2 M). The prepared solution was deoxygenated by a stream of N2 (g) for 30 minutes at room temperature. The reaction mixture was kept at 60 ° C inside a temperature controlled oven for 24 hours. Finally, the product obtained was purified by dialysis and lyophilized so that a white amorphous powder was obtained with the parameters:
    [0144] • Feed composition F mve = 0.15;
    [0145] • Composition in copolymer fMVE = 0.40
    [0146] • Yield,% by weight = 59;
    [0147] • Weight average molecular weight Mw 10-3 = 29.3;
    [0148] • Average molecular weight in number Mn • 10-3 = 18;
    [0149] • Polydispersity index Pdl = 1.9.
    [0150]
    [0151] The molar composition of the prepared copolymers was calculated from their corresponding 1 H-NMR spectra. Figure 3 shows the spectrum of the copolymer prepared from molar fractions in the MVE feed: VP 15:85. The disappearance of the characteristic signals of the vinyl protons is observed. In addition, the widening of the signals as a consequence of the polymerization and with it, of the macromolecular nature of the synthesized polymers is appreciated.
    [0152]
    [0153] For the calculation of the molar compositions of the copolymer, the values of the normalized integrals of the characteristic signals of each monomer are considered. Specifically, the signals that appear in the range of 3-5 ppm corresponding to 3 protons of the VP and 4 protons of the MVE (CH2-13 and CH2-14) and the signal at 0.86 ppm corresponding to 12 protons of the MVE (CH3-4a ', CH3-8a', CH3-12a 'and CH3-13'.
    [0154]
    [0155] The average molecular weights in weight ( Mw), in number (Mn) and the polydispersity index (£>) are obtained by size exclusion chromatography (SEC). For this, a Perkin-Elmer chromatograph equipped with an isocratic pump Series LC-250, connected to a Series 200 refractive index detector was used. The samples were eluted using three series connected columns of polymerirenedivinylbenzene (Polymer Laboratories) in size of pore of 103, 104 and 105 A at 30 ° C. As eluent tetrahydrofuran (THF) was used at a flow rate of 1 ml / min. For calibration, methyl polymethacrylate standards of molecular weight between 10,300 and 1,400,000 Da were used.
    [0156]
    [0157] To know the microstructural organization of the polymer chains and the reactivity of each of the monomers, the reactivity ratios between the monomers were calculated by quantitative analysis of 1 H-NMR in situ.
    [0158]
    [0159] The copolymerization was carried out in an NMR system using deuterated dioxane as solvent at 60 ° C. The reactions were carried out within the previous resonance tube deoxygenation with nitrogen and placing a capillary tube with dichlorobenzene inside that will serve as a reference signal. Different concentrations of comonomers were studied in order to cover the entire range of concentrations, the total concentration of monomers being 0.25 M.
    [0160]
    [0161] With this procedure, it is found that the MVE is considerably more reactive than the VP (rVP = 0.03 and rMVE = 2.20) and, therefore, the large difference in reactivity of the monomers used. This results in macromolecular chains with long sequences of both monomers and few intermediate composition chains. This compositional gradient along the macromolecular chains together with the different hydrophilicity of the monomers gives rise to multi-micellar type self-assembled polymeric structures.
    [0162]
    [0163] Example 2
    [0164]
    [0165] Preparation of terpolymers derived from MVE, VP and VC: poly (MVE-co-VP-co-VC) Using the same methodology described in Example 1, vitamin E methacrylate terpolymers (MVE), N-vinyl pyrrolidone (N-vinyl pyrrolidone) have been prepared ( VP) and N-vinyl caprolactone (VC) with the molar compositions in the food that are summarized in Table 1. The synthesized terpolymers are characterized by 1 H-NMR and SEC to know their real composition and molecular weight, obtaining the collected results. in table 1.
    [0166]
    [0167] Table 1 : Molar fractions in the feed and in the different polymer systems, including molecular weight and polydispersity data (£>) obtained by NMR and SEC, respectively
    [0168]
    [0169]
    [0170]
    [0171]
    [0172] Example 3
    [0173] Preparation of nanoparticles from poly ( MVE-co-VP) copolymers and poly ( MVE-co-VP-VC) terpolymers .
    [0174]
    [0175] Unloaded nanoparticles were prepared from poly (MVE-co-VP) and poly (MVE-co-VP-co-VC) terpolymers, synthesized by the nanoprecipitation method. For this, the copolymers and terpolymers 20 (10mg / ml) were dissolved in a water-miscible organic solvent, using dioxane in this case, although it is possible to use other miscible solvents with aqueous media such as dimethylsulfoxide, dimethylformamide, tetrahydrofuran or mixtures thereof. Then, this solution was added dropwise and with vigorous stirring, over the necessary amount of the aqueous medium to obtain a concentration of nanoparticles between 0.01 and 10 mg / ml. For cell assays, nanoparticle solutions were prepared under different conditions that are described in the following sections.
    [0176]
    [0177] The size distribution of the nanoparticles was determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS equipment (Malvern Instruments) equipped with a He-Ne laser at 633 nm and at an angle of 173 °. The measurements were carried out in polystyrene cuvettes at room temperature. Table 2 shows the particle sizes obtained, as well as the polydispersity for NPs obtained from copolymers and terpolymers previously synthesized. In all cases, the particle size varies between 130 and 185 nm with low polydispersity values.
    [0178]
    [0179] Table 2 : Hydrodynamic diameter (Dh) and polydispersity (PDI) of the nanoparticles obtained from the copolymers Poly (MVE- co -VP) and terpolymers Poly (MVE co -VP- co -VC) synthesized
    [0180]
    [0181]
    [0182]
    [0183]
    [0184] The morphology of the nanoparticles was observed by Scanning Electron Microscopy (SEM, Philips XL 30 ESEM) and Atomic Force Microscopy (AFM) using the intermittent contact mode ( tapping). For this, a drop of the nanoparticle suspension at a 1:50 dilution that was allowed to dry for 24 hours on a 14 mm glass disk. Figure 5 includes the images obtained in such a way that it is verified that the particles are spherical and do not tend to aggregate. Viability tests were performed using human fibroblasts that were maintained and multiplied at 37 ° C in an atmosphere with 5% CO2, using DMEM as a culture medium, supplemented with 10% fetal bovine serum, 1% of a solution of penicillin-streptomycin and 2% L-glutamine.
    [0185]
    [0186] The feasibility test was carried out by means of an AlamarBlue test and different dilutions of the NPs in PBS, testing concentrations between 2 and 0.06 mg / mL. Specifically, the Alamar Blue reagent is a redox indicator that changes color in response to the chemical reduction of the culture medium that occurs as a result of cell growth and proliferation.
    [0187]
    [0188] After a period of 24 h cell growth in an atmosphere with 5% CO 2 , the culture medium was exchanged for 50 pl of the nanoparticle solutions that were kept in contact with the cells for 24 hours in The same conditions. After this period of time, the contents of the wells were removed and a solution of the AlamarBlue reagent was added which was allowed to act for 3 hours. Finally, the fluorescence readings were carried out at 460/630 em / ex.
    [0189]
    [0190] Figure 6 shows the results of cell viability for NPs prepared from the poly control copolymer (MVE-co-VP) and the various poly terpolymers (MVE-co-VP-co-VC). In view of the results represented, none of the concentrations of NPs are cytotoxic, maintaining cell viability above 90% without significant differences with respect to control.
    [0191]
    [0192] Example 4
    [0193]
    [0194] Preparation of nanoparticles loaded with dexamethasone from copolymers poly ( MVE-co-VP) and terpolymers poly ( MVE-co-VP-co-VC).
    [0195] One of the greatest attractions of the prepared nanoparticles is the possibility of being able to be used very effectively as vehicles of insoluble or poorly soluble bioactive compounds in aqueous media. The following experiments demonstrate the ability of nanoparticles prepared with copolymers and terpolymers considered in this patent. Although the results have been limited to the dexamethasone loading, as an active compound with anti-inflammatory activity, the nanoparticles of copolymers and terpolymers can be loaded and used as vehicles for a wide variety of bioactive compounds and medications, with the sole condition that they should if they are insoluble or poorly soluble in aqueous media or physiological medium, which thus offers a very appropriate route for the application in the human body of systems that have an absorption limit due to their low solubility in the physiological environment. The application is not limited to a specific family of bioactive components or medications of difficult or limited administration. This opens up a very attractive scenario for localized administration, directed and sustained by any means of a wide range of possibilities with its advantage from a therapeutic point of view.
    [0196]
    [0197] The charged nanoparticles were prepared at a concentration of 2 mg / ml in PBS and in NaCl starting from a concentration of the copolymer in dioxane of 50 mg / ml. Additionally, a concentration of 15% by weight with respect to the polymer of the active molecule, dexamethasone (Dx) was added in this case. The procedure is similar to that described for the NPs without charge, so that the organic phase was allowed to drip onto the aqueous one (PBS or 100 mM NaCl), to finally dialyze the resulting solution for 3 days.
    [0198]
    [0199] To calculate the encapsulation efficiency (EE) of dexamethasone, the different NPs prepared were lyophilized to eliminate the aqueous phase, obtaining a white powder with a yield of approximately 90%. Then, 5 mg of each formulation was dissolved in chloroform for 24 hours, then add 2mL of ethanol and stir for 24 hours until the precipitation of the polymer was observed. The samples obtained were centrifuged at 10,000 rpm and the supernatant was analyzed by UV (NanoDrop One Thermo Scientific) at a wavelength of 239 nm corresponding to dexamethasone.
    [0200]
    [0201] The size distribution of the nanoparticles was determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS equipment (Malvern Instruments) equipped with a Helium-Neon laser at 633 nm and with detection at an angle of 173 °. The measurements were made in polystyrene cuvettes at room temperature.
    [0202] Table 3 shows the sizes, polydispersity and EE of the particles loaded with Dx, obtained from the copolymers poly (MVE-co-VP), of the terpolymers poly (MVE-co-VP-co-VC) and different mixtures of both polymer systems.
    [0203]
    [0204] Table 3 : Hydrodynamic diameter (Dh) and polydispersity (PDI) of nanoparticles loaded with dexamethasone obtained from Poly copolymers (MVE-co-VP) and Poly terpolymers (MVE-co-VP-co-VC) synthesized as well as different mixtures
    [0205]
    [0206]
    [0207]
    [0208]
    [0209] The size distribution obtained for NPs loaded with dexamethasone from poly (MVE-co-VP) copolymers, poly (MVE-co-VP-co-VC) terpolymers and mixtures of both polymer systems is in a range from 140 to 170 nm, with low polydispersities and distributions of unimodal sizes.
    [0210]
    [0211] Example 5
    [0212]
    [0213] Study of the stability of the different nanoparticles obtained from poly ( MVE-co-VP) and poly ( MVE-co-VP-co-VC) copolymers .
    [0214] To study the effect that the storage method can have on stability The size of the multi-micellar nanoparticles was cooled in the refrigerator, frozen at -20 ° C and lyophilized, as described below.
    [0215] • Refrigeration in refrigerator:
    [0216] For 4 continuous weeks (1 month), the size distribution of the control NPs empty and loaded with Dx and obtained from the poly (MVEco-VP) copolymers was measured. The results obtained, Dh and PDI, throughout each week are compiled in table 4.
    [0217]
    [0218] Table 4 : Evolution of particle size and polydispersity during maintenance in the refrigerator at 4 ° C of the control nanoparticles obtained from poly (MVE-co-VP) copolymers.
    [0219]
    [0220]
    [0221]
    [0222]
    [0223] Figure 7 compares the particle size distributions for empty and charged particles, prepared in both PBS and NaCl. The initial results (S0, freshly prepared NPs) as well as the curves are shown after each week of storage at 4 ° C. The samples measured in each week are named S1 (week 1), S2 (week 2), S3 (week 3) and S4 (week 4).
    [0224]
    [0225] Table 4 and Figure 7 show the distribution of sizes obtained after 4 weeks of storage of the NPs in a refrigerator (4 ° C) for the different NPs. It can be seen that the results are similar during the 4 weeks of storage in addition to being similar with the original sizes distribution (week 0) for all types of NPs, in general. This behavior is analogous to that observed with the NPs obtained from the different terpolymers poly (MVE-co-VP-co-VC) synthesized.
    [0226]
    [0227] For 4 weeks, the size distribution of the control NPs was measured to observe their behavior after being stored under freezing at -20 ° C. The measurement protocol was carried out by continuous freezing weeks (1, 2, 3 and 4 weeks), that is, 4 different samples were used, each defrosted and thawed at different times.
    [0228]
    [0229] Next, in table 5 the size distribution obtained for each type of NPs can be observed for four weeks, including the respective polydispersities (PDI). As a result, stable NPs are observed, where size variations are not significant, with low polydispersity values.
    [0230]
    [0231] Table 5 : Evolution of particle size and polydispersity during maintenance in the freezer at -20 ° C of the control nanoparticles obtained from poly (MVE-co-VP) copolymers.
    [0232]
    [0233]
    [0234]
    [0235] Figure 8 (a) Distribution of NPs in PBS without charge, b) NaCl without charge, c) 15% dexamethasone in PBS and d) 15% dexamethasone in NaCl respectively) shows the size distribution of synthesized NPs, measured during different freezing times as mentioned previously.
    [0236] The graphs show that the curves obtained are similar to the sizes of week 0, the overlapping of the curves corresponding to each freezing week can also be observed. This behavior is the same for all types of synthesized NPs, both for those obtained from poly (MVE-co 20 VP) copolymers and from poly (MVE-co-VP-co-VC) terpolymers. Thus, it can be said that all NPs are stable after one month of storage under the detailed conditions. Furthermore, the formation of agglomerates is not observed since there is absence of secondary peaks in the curves.
    [0237]
    [0238] From each type of nanoparticles, 3mL was lyophilized for 2 days, then resuspended in the same volume of Mili-Q ultrapure water. Subsequently, the size distribution was measured after 2 hours of magnetic stirring at a speed of 1000 rpm and 5 or 10 minutes under the application of ultrasound (Sonics Vibra-Cell) at 29% amplitude (1 / 2W / tip) in bath of ice. The results obtained are compiled in Table 6 and the particle size distributions are compared in Figure 9.
    [0239]
    [0240] In view of the results compiled in table 6, distribution of sizes after 2 hours of magnetic stirring are greater than the original diameters in addition to showing second peaks with diameters of larger sizes, for this reason we proceeded to apply 5 minutes of ultrasound to Obtain the desired diameters.
    [0241]
    [0242] In table 6 it can be observed that after 5 minutes of ultrasound, there is presence of second peaks and distribution of sizes larger than the original ones (Week 0), for this reason it was necessary to apply ultrasound 10 minutes more, the secondary peaks do not disappear, but they decrease, as for the size distribution, although they are slightly larger (around 180 nm), they approach the original diameters (approximately 150 nm). These results show that not only magnetic stirring after resuspending is sufficient, but the application of ultrasound for at least 10 minutes is necessary.
    [0243]
    [0244] In order to eliminate the use of ultrasound and only use magnetic stirring after lyophilization, NPs were synthesized again incorporating a stabilizing agent TGPS or a-tocopherol polyethylene glycol 1000-succinate (R14-M043 Sigma-Aldrich) by two different methods:
    [0245] 1. Incorporating 0.02% wt TPGS in the synthesis of NPs, with respect to all the volume (only NPs loaded with 15% dexamethasone were synthesized).
    [0246] 2. Resuspend in an ultrapure water solution (Mili Q) with 0.02% TGPS. The results are shown below.
    [0247]
    [0248] In figure 10 it can be observed in all cases that it was not enough with 2 hours of magnetic stirring to obtain the original diameters, despite incorporating a certain amount of TPGS. For this reason, ultrasound was applied (under the same conditions specified above) for 5 minutes, even so, the size distribution was much larger than the original before resuspended, so the NPs were subjected to 20 more minutes of ultrasound, where if a distribution of sizes very close to the original is observed in all cases.
    [0249]
    [0250] Table 6 : Particle size and polydispersity after lyophilizing the control nanoparticles obtained from poly (MVE-co-VP) copolymers and subjected to magnetic stirring or ultrasound (US).
    [0251]
    [0252]
    [0253]
    [0254]
    [0255] Finally, the addition of TPGS can be affirmed, by either of the two methods it does not significantly improve obtaining the original size distribution after resuspending and subjecting the NPs to 2 hours of magnetic stirring, it is
    [0256] 5 necessary to apply at least 20 minutes ultrasound.
    [0257]
    [0258] Example 6
    [0259]
    [0260] Scaling in the preparation of control polymer nanoparticles obtained from poly ( MVE-co-VP) copolymers
    [0261] In order to synthesize higher volumes of NPs, they were synthesized using the same protocol, but at higher speeds of agitation NPs. The size distribution obtained for 30 and 50 mL of NPs are collected in table 7.
    [0262]
    [0263] Table 7 : Particle size and polydispersity after scaling in the preparation of the control nanoparticles obtained from poly (MVE-co-VP) copolymers.
    [0264]
    [0265] Sample Volume (mL) Dh (nm) PDI 30 145 ± 1 0.10 ± 0.01 No load
    [0266] Cop-85-PBS 50 145 ± 2 0.09 ± 0.01
    [0267] 15% DX 30 146 ± 1 0.07 ± 0.01
    [0268] 50 148 ± 1 0.10 ± 0.02 30 138 ± 1 0.07 ± 0.01 No load 50 144 ± 1 0.09 ± 0.02 Cop-85-NaCl
    [0269] 15% DX 30 123 ± 1 0.11 ± 0.03
    [0270] 50 136 ± 2 0.09 ± 0.02
    [0271]
    [0272] After the scaling in the preparation of the NPs, it can be observed that the size distribution obtained is similar to greater volume, so it could be said that the NPs preparation protocol is valid with higher volumes, with the only variation of increasing the stirring speed during the synthesis of NPs.
    权利要求:
    Claims (15)
    [1]
    l.-Polymeric compound of formula (I):

    [2]
    2. - Compound according to claim 1 wherein vitamin E is alpha-tocopherol.
    [3]
    3. Compound according to any of claims 1 or 2 wherein G and J are independently selected from the following group: W-vinyl pyrrolidone, N-vinylcaprolactam, 1-vinylimidazole and W, W-dimethylacrylamide, W-isopropylacrylamide, 2-hydroxyethyl methacrylate, 2 --hydroxyethyl acrylate, polyethylene glycol methacrylate, polyethylene glycol acrylate, 2-hydroxypropyl methacrylate, W-ethylmorpholine methacrylate, W-ethylmorpholine acrylate, W-hydroxyethyl pyrrolidone acrylate, W-hydroxyethyl pyrrolidone acrylate.
    [4]
    4. Polymeric compound according to any one of claims 1 to 3, wherein said compound is the compound of formula (II):

    [5]
    5. Polymeric compound according to any of claims 1 to 3, wherein said compound is the compound of formula (III):

    [6]
    6. - Polymeric compound according to any of the preceding claims wherein m has a value of 0.15.
    [7]
    7. Polymeric compound according to any of the preceding claims wherein n has a value between 0.00 and 0.85.
    [8]
    8. Polymeric compound according to any of the preceding claims wherein n ’has a value between 0.00 and 0.85.
    [9]
    9. Multi-micellar nanoparticle comprising the polymeric compound according to any one of claims 1 to 8.
    [10]
    10. - Multi-micellar nanoparticle according to claim 9 wherein said polymeric compound is the compound of formula (II).
    [11]
    11. - Multi-micellar nanoparticle according to claim 9 wherein said polymeric compound is the compound of formula (III).
    [12]
    12. Multi-micellar nanoparticle according to claim 9 further comprising a bioactive compound.
    [13]
    13. Multi-micellar nanoparticle according to claim 12, wherein the bioactive compound is selected from the following group: methylprednisolone, dexamethasone, cortisone, ibuprofen, naproxen, flurbiprofen, ketoprofen, vitamin C, polyphenols, carnosic acid, astaxanthin, vitamin B1, vitamin B6, vitamin B12, derivatives of pcarotene, lutein, allantoin, vitamin A, folic acid, vancomycin, rifampin, linezolid, quaternary ammonium salts, chlorhexidine.
    [14]
    14. - Controlled release system of bioactive compounds comprising the multi-micellar nanoparticle according to any of claims 9 to 13.
    [15]
    15. Pharmaceutical composition comprising the controlled release system according to claim 14.
    类似技术:
    公开号 | 公开日 | 专利标题
    Xiong et al.2017|Stimuli-responsive shell cross-linked micelles from amphiphilic four-arm star copolymers as potential nanocarriers for “pH/redox-triggered” anticancer drug release
    Qiao et al.2011|Multi-responsive nanogels containing motifs of ortho ester, oligo | and disulfide linkage as carriers of hydrophobic anti-cancer drugs
    Kim et al.2010|Hydrogen bonding-enhanced micelle assemblies for drug delivery
    Gupta et al.2012|Poly | micelles for reactive oxygen species triggered drug release
    Khorsand et al.2013|Intracellular drug delivery nanocarriers of glutathione-responsive degradable block copolymers having pendant disulfide linkages
    Wei et al.2009|Thermo-sensitive polymeric micelles based on poly | as drug carriers
    Duong et al.2011|Acid degradable and biocompatible polymeric nanoparticles for the potential codelivery of therapeutic agents
    Yang et al.2011|pH-sensitive micelles self-assembled from amphiphilic copolymer brush for delivery of poorly water-soluble drugs
    US8367051B2|2013-02-05|Preparation of functional gel particles with a dual crosslink network
    Luxenhofer et al.2010|Doubly amphiphilic poly | s as high-capacity delivery systems for hydrophobic drugs
    Huh et al.2005|Hydrotropic polymer micelle system for delivery of paclitaxel
    Geng et al.2006|Visualization of degradable worm micelle breakdown in relation to drug release
    Deng et al.2015|Balancing the stability and drug release of polymer micelles by the coordination of dual-sensitive cleavable bonds in cross-linked core
    Giacomelli et al.2011|pH-triggered block copolymer micelles based on a pH-responsive PDPA | ethyl methacrylate]) inner core and a PEO |) outer shell as a potential tool for the cancer therapy
    Yang et al.2012|Synthesis and physicochemical characterization of amphiphilic triblock copolymer brush containing pH-sensitive linkage for oral drug delivery
    Yao et al.2011|ABC block copolymer as “smart” pH-responsive carrier for intracellular delivery of hydrophobic drugs
    San Miguel et al.2008|Biodegradable and thermoresponsive micelles of triblock copolymers based on 2-| ethyl methacrylate and ε-caprolactone for controlled drug delivery
    Xu et al.2017|pH-responsive polymeric micelles based on poly |-b-poly | ethyl methacrylate) block copolymer for enhanced intracellular release of anticancer drugs
    Asadi et al.2016|Dual responsive nanogels for intracellular doxorubicin delivery
    Bao et al.2018|Self-stabilized, hydrophobic or PEGylated paclitaxel polymer prodrug nanoparticles for cancer therapy
    Lin et al.2017|Well-defined star polymers for co-delivery of plasmid DNA and imiquimod to dendritic cells
    Washington et al.2017|Thermoresponsive star-like γ-substituted poly | s for micellar drug delivery
    Blanco-Fernandez et al.2017|Dually sensitive dextran-based micelles for methotrexate delivery
    Michailova et al.2010|Nanoparticles formed from PNIPAM-g-PEO copolymers in the presence of indomethacin
    Najafi et al.2018|Native chemical ligation for cross-linking of flower-like micelles
    同族专利:
    公开号 | 公开日
    EP3583939A1|2019-12-25|
    ES2735638B2|2021-01-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    ES2433248A1|2012-05-07|2013-12-10|Consejo Superior De Investigaciones Científicas |Amphiphilic copolymers carrying alpha-tocopherol having antitumoural properties|
    US20180147318A1|2015-05-18|2018-05-31|Juana Mendenhall|Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same|
    FR2952936B1|2009-11-26|2011-11-25|Flamel Tech|ACRYLIC OR METHACRYLIC TYPE POLYMER COMPRISING ALPHA-TOCOPHEROL GRAFT|EP3884963A1|2020-03-26|2021-09-29|Consejo Superior de Investigaciones Científicas |Naproxen/dexamethasone-based nanoparticles|
    法律状态:
    2019-12-19| BA2A| Patent application published|Ref document number: 2735638 Country of ref document: ES Kind code of ref document: A1 Effective date: 20191219 |
    2021-01-18| FG2A| Definitive protection|Ref document number: 2735638 Country of ref document: ES Kind code of ref document: B2 Effective date: 20210118 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201830594A|ES2735638B2|2018-06-18|2018-06-18|AUTO-ASSOCIATED FUNCTIONAL ACRYLIC COPOLYMERS AND TERPOLYMERS AND THEIR USE AS VEHICLES FOR BIOACTIVE COMPOUNDS|ES201830594A| ES2735638B2|2018-06-18|2018-06-18|AUTO-ASSOCIATED FUNCTIONAL ACRYLIC COPOLYMERS AND TERPOLYMERS AND THEIR USE AS VEHICLES FOR BIOACTIVE COMPOUNDS|
    EP19382505.6A| EP3583939A1|2018-06-18|2019-06-18|Autoassociative acrylic functional copolymers and terpolymers and their use as vehicles of bioactive compounds|
    [返回顶部]